Sulbutiamine and fatigue

What 3 graded rows on sulbutiamine agree on for fatigue, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Sulbutiamine page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Sulbutiamine page, with its PubMed record.

Your question

Fatigue3

Supplement

Sulbutiamine Choose another

Sulbutiamine and fatigue

3 rows · 2,124 people

Mostly an improvement: 2 of 3 rows, and most of the people. 1 found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

Grade D× 2
No effect× 1

Rows: 3
Trials: 3
People: 2,124

Where they differ

From the rows

Trial sizeWhen published

The best-graded row, grade D, is an observational study of 1,772 people (2003) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.

The 2 rows that found an improvement were larger: a median of 899 people, against 326 people for the row that found no difference.

The 2 rows that found an improvement are newer (2003 to 2017) than the row that found no difference (1999).

The rows

2 improved · 1 no difference

Grade DWeakness and fatigue during infection (added to anti-infective drugs) · Improved
Observational · n 1,772 · 2003 · Patients with infections and weakness symptoms seen by 350 physicians (India)
Not stated in the abstract · 15 days
51.7% reported complete resolution of weakness symptoms; side effects were reported in 0.6%.
Row on the Sulbutiamine page · PubMed 14710977 (opens PubMed)
Grade DFatigue in multiple sclerosis · Improved
Open-label trial · n 26 · 2017 · Adults with multiple sclerosis and prominent fatigue (Turkey)
400 mg/day · 2 months
Fatigue Impact Scale total fell from 77 to 60.5 (P < 0.01) with no serious adverse events; clear improvement was seen in 13 of 23 people also on disease-modifying drugs and in none of the 5 who were not.
Row on the Sulbutiamine page · PubMed 28755683 (opens PubMed)
No effectChronic post-infection fatigue · No difference
RCT · n 326 · 1999 · General-practice patients with chronic post-infectious fatigue (France)
400 or 600 mg/day · 28 days
No overall difference from placebo on a validated multidimensional fatigue scale or other measures; women on 600 mg had less fatigue on day 7 only, with no effect at day 28. 315 of 326 completed.
Row on the Sulbutiamine page · PubMed 10573727 (opens PubMed)

NextRead the full evidenceThe full evidence chapter on its page, with every outcome and its sources.